Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of infant MenB vaccination persistence and booster/catch-up immunogenicity in UK children
2009-013075-21Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (4 cohorts), sponsored by Novartis. Primary endpoints: Serum bactericidal antibody persistence at approximately 40 months of age, Booster dose immunogenicity at approximately 40 months of age and 5 more. Started Jul 2009; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2009-013075-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013075-21.